A Phase 1 interventional study of PF-07853578 and Placebo in Healthy Participants, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-03.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purposes of this study are:
This study is seeking for participants who:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.
Drug: PF-07853578 · Drug: Placebo
Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.
Drug: PF-07853578 · Drug: Placebo
Single dose administration of PF-07853578 and placebo. Participants will receive up to 4 dose levels of PF-07853578 and up to 2 dose levels of matching placebo.
Drug: PF-07853578 · Drug: Placebo
PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.
Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An adverse event is considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were flagged as TEAEs. The algorithm did not consider any events that started prior to the first dose date. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Day 1-11 in each period, along with the 29-36 day post final dose follow-up
Number of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline Abnormality
Pre-defined categorical criteria for laboratory abnormalities included: Lymphocytes \<0.8 x lower limit of normal (LLN); Basophils/Leukocytes \> 1.2 x upper limit of normal (ULN); Eosinophils/Leukocytes \>1.2 x ULN; Monocytes/Leukocytes \>1.2 x ULN; low-density lipoprotein (LDL) Direct Endpoint Measure \>1.2 x ULN; Triglycerides \>1.3 x ULN; Specific Gravity \<1.003 or \>1.030; pH \>8; Ketones ≥1; Urobilinogen (EU) ≥1; URINE Bilirubin ≥1; Leukocyte Esterase ≥1.
Time frame: Day 1-11 in each period, along with the 29-36 day post final dose follow-up
Number of Participants With Vital Signs Abnormalities Meeting Pre-Defined Categorical Criteria
Vital signs categorical criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (≥) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP ≥ 20 mmHg.
Time frame: Day 1-11 in each period, along with the 29-36 day post final dose follow-up
Number of Participants With Abnormal Electrocardiogram (ECG) Meeting Pre-Defined Categorical Criteria
ECG categorical criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) ≥300 millisecond (msec), b) ≥25% increase when baseline is \> 200 msec, c) ≥50% increase when baseline is less than or equal to (≤) 200 msec. 2\. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) ≥140 msec, b) ≥50% increase from baseline. 3\. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and ≤480 msec, b) \>480 msec and ≤500 msec, c) \>500 msec, d) \>30 msec and ≤60 msec increase from baseline, e) \>60 msec increase from baseline.
Time frame: Day 1-11 in each period, along with the 29-36 day post final dose follow-up
Maximum Concentration Observed in Plasma (Cmax)
Maximum observed plasma PF-07328948 concentration. Observed directly from data.
Time frame: Pre-dose (0 hour) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)
Time to Achieve Cmax (Tmax)
Observed directly from data as time of first occurrence.
Time frame: Pre-dose (0 hour) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measured Concentration (AUClast)
Area under the plasma concentration time-curve from zero to the last measured concentration. It was determined by using linear/Log trapezoidal method.
Time frame: Pre-dose (0 hours) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)
Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
Area under the plasma concentration-time curve from time 0 extrapolated to infinite time. AUCinf = AUClast + (Clast\*/kel), where Clast\* was the predicted plasma concentration at the last quantifiable timepoint estimated from the log-linear regression analysis, and Kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, AUClast = Area under the plasma concentration time-curve from zero to the last measured concentration.
Time frame: Pre-dose (0 hour) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)
Terminal Half-Life (t1/2)
Terminal elimination half-life. t1/2 = Loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.
Time frame: Pre-dose (0 hour) and 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours and 12 hours post Day 1 dosing of each treatment period (Periods 1-4)
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 |
|---|---|---|---|
| Started | 8 | 8 | 7 |
| Completed | 6 | 6 | 7 |
| Not completed | 2 | 2 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Other | 1 | 2 | 0 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An adverse event is considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were flagged as TEAEs. The algorithm did not consider any events that started prior to the first dose date. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Participants | PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution) | 3 mg | 8 mg | 8 mg (Intermediate Dosage Strength [IDS] Solution) | 10 mg | 30 mg | 100 mg | 300 mg | 300 mg Fed | 500 mg | Placebo Fasted | Placebo Fed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All-causality AEs | 1 | 2 | 3 | 2 | 2 | 1 | 0 | 1 | 4 | 0 | 3 | 0 |
| Treatment-related AEs | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| All-causality SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treatment-related SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Pre-defined categorical criteria for laboratory abnormalities included: Lymphocytes \<0.8 x lower limit of normal (LLN); Basophils/Leukocytes \> 1.2 x upper limit of normal (ULN); Eosinophils/Leukocytes \>1.2 x ULN; Monocytes/Leukocytes \>1.2 x ULN; low-density lipoprotein (LDL) Direct Endpoint Measure \>1.2 x ULN; Triglycerides \>1.3 x ULN; Specific Gravity \<1.003 or \>1.030; pH \>8; Ketones ≥1; Urobilinogen (EU) ≥1; URINE Bilirubin ≥1; Leukocyte Esterase ≥1.
| Participants | PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution) | 3 mg | 8 mg | 8 mg (Intermediate Dosage Strength [IDS] Solution) | 10 mg | 30 mg | 100 mg | 300 mg | 300 mg Fed | 500 mg | Placebo Fasted | Placebo Fed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline Abnormality | 4 | 5 | 5 | 4 | 5 | 5 | 4 | 4 | 2 | 1 | 11 | 1 |
Vital signs categorical criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (≥) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP ≥ 20 mmHg.
| Participants | PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution) | 3 mg | 8 mg | 8 mg (Intermediate Dosage Strength [IDS] Solution) | 10 mg | 30 mg | 100 mg | 300 mg | 300 mg Fed | 500 mg | Placebo Fasted | Placebo Fed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DBP <50 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Pulse rate < 40 bpm | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate > 120 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SBP <90 mmHg | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 |
| Change from baseline in DBP ≥20 increase | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change from baseline in DBP ≥20 decrease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Change from baseline in SBP ≥30 mmHg increase | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change from baseline in SBP ≥30 mmHg decrease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
ECG categorical criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) ≥300 millisecond (msec), b) ≥25% increase when baseline is \> 200 msec, c) ≥50% increase when baseline is less than or equal to (≤) 200 msec. 2\. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) ≥140 msec, b) ≥50% increase from baseline. 3\. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and ≤480 msec, b) \>480 msec and ≤500 msec, c) \>500 msec, d) \>30 msec and ≤60 msec increase from baseline, e) \>60 msec increase from baseline.
| Participants | PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution) | 3 mg | 8 mg | 8 mg (Intermediate Dosage Strength [IDS] Solution) | 10 mg | 30 mg | 100 mg | 300 mg | 300 mg Fed | 500 mg | Placebo Fasted | Placebo Fed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Abnormal Electrocardiogram (ECG) Meeting Pre-Defined Categorical Criteria | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Maximum observed plasma PF-07328948 concentration. Observed directly from data.
| nanogram per milliliter (ng/mL) | PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution) | 3 mg | 8 mg | 8 mg (Intermediate Dosage Strength [IDS] Solution) | 10 mg | 30 mg | 100 mg | 300 mg | 300 mg Fed | 500 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Concentration Observed in Plasma (Cmax) | 7.196 ± 14 | 7.226 ± 52 | 14.87 ± 66 | 41.92 ± 41 | 17.92 ± 35 | 43.91 ± 45 | 119.8 ± 38 | 355.6 ± 39 | 690.6 ± 53 | 449.2 ± 51 |
Observed directly from data as time of first occurrence.
| hours (hr) | PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution) | 3 mg | 8 mg | 8 mg (Intermediate Dosage Strength [IDS] Solution) | 10 mg | 30 mg | 100 mg | 300 mg | 300 mg Fed | 500 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Time to Achieve Cmax (Tmax) | 0.500 (0.500 to 1.00) | 1.08 (0.500 to 1.17) | 1.00 (0.500 to 1.00) | 0.517 (0.500 to 0.517) | 1.00 (0.500 to 2.00) | 2.00 (1.00 to 2.00) | 3.00 (2.00 to 3.02) | 2.00 (1.00 to 3.00) | 4.00 (2.00 to 6.00) | 3.02 (2.00 to 6.00) |
Area under the plasma concentration time-curve from zero to the last measured concentration. It was determined by using linear/Log trapezoidal method.
| nanogram*hour per milliliter (ng*hr/mL) | PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution) | 3 mg | 8 mg | 8 mg (Intermediate Dosage Strength [IDS] Solution) | 10 mg | 30 mg | 100 mg | 300 mg | 300 mg Fed | 500 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measured Concentration (AUClast) | 17.03 ± 30 | 43.52 ± 77 | 105.8 ± 62 | 111.6 ± 44 | 153.3 ± 33 | 462.4 ± 54 | 1825 ± 31 | 4590 ± 58 | 6747 ± 66 | 7774 ± 25 |
Area under the plasma concentration-time curve from time 0 extrapolated to infinite time. AUCinf = AUClast + (Clast\*/kel), where Clast\* was the predicted plasma concentration at the last quantifiable timepoint estimated from the log-linear regression analysis, and Kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, AUClast = Area under the plasma concentration time-curve from zero to the last measured concentration.
| ng*hr/mL | PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution) | 3 mg | 8 mg | 8 mg (Intermediate Dosage Strength [IDS] Solution) | 10 mg | 30 mg | 100 mg | 300 mg | 300 mg Fed | 500 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf) | 18.29 ± 31 | 46.69 ± 73 | 111.5 ± 60 | 114.1 ± 44 | 157.0 ± 33 | 470.6 ± 55 | 1876 ± 29 | 4649 ± 59 | 6822 ± 67 | 8066 ± 27 |
Terminal elimination half-life. t1/2 = Loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.
| hours (hr) | PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution) | 3 mg | 8 mg | 8 mg (Intermediate Dosage Strength [IDS] Solution) | 10 mg | 30 mg | 100 mg | 300 mg | 300 mg Fed | 500 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Terminal Half-Life (t1/2) | 5.748 ± 4.1227 | 12.78 ± 3.6983 | 15.19 ± 7.1273 | 8.692 ± 2.4278 | 11.26 ± 4.7825 | 13.15 ± 2.5990 | 13.00 ± 3.8601 | 10.44 ± 2.7311 | 11.28 ± 2.7070 | 14.38 ± 3.0237 |
Collected over Day 1-11 in each period, along with the 29-36 day post final dose follow-up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution) | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| 3 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| 8 mg | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| 8 mg (Intermediate Dosage Strength [IDS] Solution) | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| 10 mg | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| 30 mg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 100 mg | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| 300 mg | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 300 mg Fed | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| 500 mg | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Placebo Fasted | 0/14 (0%) | 0/14 (0%) | 3/14 (21.4%) |
| Placebo Fed | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Event | PF-07853578 1 mg (1mg) (Low Dosage Strength [LDS] Solution) | 3 mg | 8 mg | 8 mg (Intermediate Dosage Strength [IDS] Solution) | 10 mg | 30 mg | 100 mg | 300 mg | 300 mg Fed | 500 mg | Placebo Fasted | Placebo Fed |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Application site irritationGeneral disorders | 0/5 | 1/6 | 0/5 | 0/5 | 1/5 | 1/6 | 0/5 | 0/6 | 2/5 | 0/4 | 0/14 | 0/1 |
| Feeling hotGeneral disorders | 0/5 | 0/6 | 1/5 | 0/5 | 0/5 | 0/6 | 0/5 | 0/6 | 0/5 | 0/4 | 0/14 | 0/1 |
| Upper respiratory tract infectionInfections and infestations | 0/5 | 0/6 | 0/5 | 1/5 | 0/5 | 0/6 | 0/5 | 0/6 | 0/5 | 0/4 | 0/14 | 0/1 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/5 | 0/6 | 0/5 | 0/5 | 0/5 | 0/6 | 0/5 | 0/6 | 1/5 | 0/4 | 0/14 | 0/1 |
| DizzinessNervous system disorders | 0/5 | 0/6 | 0/5 | 1/5 | 0/5 | 0/6 | 0/5 | 0/6 | 0/5 | 0/4 | 0/14 | 0/1 |
| HeadacheNervous system disorders | 0/5 | 1/6 | 0/5 | 1/5 | 1/5 | 0/6 | 0/5 | 0/6 | 0/5 | 0/4 | 1/14 | 0/1 |
| SomnolenceNervous system disorders | 0/5 | 0/6 | 1/5 | 0/5 | 0/5 | 0/6 | 0/5 | 0/6 | 0/5 | 0/4 | 0/14 | 0/1 |
| Tension headacheNervous system disorders | 0/5 | 0/6 | 0/5 | 0/5 | 0/5 | 0/6 | 0/5 | 0/6 | 1/5 | 0/4 | 0/14 | 0/1 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/5 | 0/6 | 1/5 | 0/5 | 0/5 | 0/6 | 0/5 | 0/6 | 0/5 | 0/4 | 0/14 | 0/1 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 1/5 | 0/6 | 0/5 | 0/5 | 0/5 | 0/6 | 0/5 | 0/6 | 0/5 | 0/4 | 0/14 | 0/1 |
| Age, Customized(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| 18-44 years | 6 | 5 | 6 | 17 |
| 45-64 years | 2 | 3 | 1 | 6 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| Female | 1 | 1 | 0 | 2 |
| Male | 7 | 7 | 7 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 1 | 3 |
| Not Hispanic or Latino | 7 | 7 | 6 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Total |
|---|---|---|---|---|
| White | 3 | 4 | 1 | 8 |
| Black or African American | 3 | 2 | 5 | 10 |
| Asian | 2 | 1 | 1 | 4 |
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jun 2023 to primary completion in Dec 2023, 5 months.
Results were first posted in Jan 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.